LUHUA WANG to Lymphoma, B-Cell
This is a "connection" page, showing publications LUHUA WANG has written about Lymphoma, B-Cell.
Connection Strength
0.675
-
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015 May; 97(5):455-68.
Score: 0.306
-
Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jul; 6(7):983-91.
Score: 0.167
-
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
Score: 0.072
-
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
Score: 0.045
-
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75.
Score: 0.038
-
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
Score: 0.037
-
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7.
Score: 0.011